Traumatic brain injury (TBI), multiple sclerosis (MS), post-traumatic epilepsy (PTE), Alzheimer's disease and related dementias (ADRD), chronic traumatic encephalopathy (CTE), and related indications are leading causes of death and disability. Gryphon Bio is a preclinical-stage therapeutic bioconjugate company created to harness our co-founders' discovery of novel therapeutic targets and temporal biomarkers in unexpected waves of brain molecules in the blood. Mission: To develop and market the 1st therapeutic bioconjugate to accelerate brain repair and improve cognition. Vision: To pioneer therapeutic bioconjugates to improve the lives of patients with neurological or neurodegenerative diseases.